Compare AbCellera Biologics Inc (ABCL) vs YieldMax AI & Tech Portfolio Option Income ETF (GPTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs YieldMax AI & Tech Portfolio Option Income ETF — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while YieldMax AI & Tech Portfolio Option Income ETF trades at $43.53. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, YieldMax AI & Tech Portfolio Option Income ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | GPTY | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $8.12 | $50.52 |
52-Week Low | $2.78 | $34.73 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GPTY trades at $44.83, up 3.15% in the last 24 hours, with technical indicators showing a bearish trend but oversold RSI signals. The ETF maintains a consistent weekly dividend payout strategy, with recent distributions ranging from $0.30 to $0.38. News highlights focus on its AI and tech portfolio exposure and option-income strategy, though technical momentum remains weak.
Outlook is mixed: high dividend yield and AI theme appeal to income investors, but bearish technicals and reliance on semiconductor momentum pose risks. Investor sentiment is cautious amid volatile tech sector performance, requiring close monitoring of NAV stability and market trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About YieldMax AI & Tech Portfolio Option Income ETF
GPTY is an actively managed ETF that seeks to provide current income and capital appreciation by holding a concentrated portfolio of 15 to 30 leading AI and technology companies. It utilizes a variety of options strategies, including selling call options on its underlying holdings, to generate weekly distributions while maintaining direct equity exposure to the growth of the AI sector.
Read more on GPTY →
